home > investor relations

Highlights

Final Results to 31 December 2009

Revenues hit £5 million for second successive year at £5.00 million (2008: £5.18 million)
Second year of profitability with operating profits at £0.46 million (2008: £0.57 million)
Cash and cash equivalents up £0.49 million at £2.07 million
Strong positive cash flow from operations at £0.90 million up £0.36 million

Commenting on the results, Steve Harris, Chairman of Cyprotex PLC, said:

"Cyprotex's results represent an impressive performance against a very difficult market currently for the pre-clinical CRO sector. Cyprotex continues to attract new customers, expand its offerings and is investing in new laboratories to service both the ADME and pre-clinical toxicology markets"

Download Final Results to 31 December 2009


July 14, 2010 Result of AGM
July 14, 2010 AGM Statement
July 2, 2010 Change of Adviser

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100